



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/507,059

09/09/2004

Hoon Choi

O-2779

8288

67283

7590

06/15/2009

MONTGOMERY, MCCrackEN, WALKER & RHOADS, LLP

123 SOUTH BROAD STREET

AVENUE OF THE ARTS

PHILADELPHIA, PA 19109

EXAMINER

BERRIOS, JENNIFER A

ART UNIT

PAPER NUMBER

1619

MAIL DATE

DELIVERY MODE

06/15/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/507,059

Applicant(s)

CHOI ET AL.

Examiner

Jennifer A. Berrios

Art Unit

1619

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 October 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7, 9-11, 20 and 27-36 is/are pending in the application.
- 4a) Of the above claim(s) 32-36 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 and 9-11, 20 and 27-30 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/808)
Paper No(s)/Mail Date 7/10/2008
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

This Office Action is in response to Applicant's amendment/response filed 10/1/2008 wherein claims 8, 12-19 and 21-26 were cancelled, claims 1-7, 9-77 and have been amended and claims 27-36 have been added.

Election/Restrictions

Claims 32-36 have been withdrawn from consideration as they are drawn to a non-elected species by original presentation.

Response to Arguments

Applicants' arguments, filed 10/1/2008, have been fully considered and are persuasive, but are moot in view of the new ground(s) of rejection. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. The limitations of the newly added claims are different in breadth and scope, and therefore the rejections from the previous Office Action, mailed 7/9/2008, have been withdrawn.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which

Art Unit: 1619

said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

3. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

4. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 1-7, 9-11, 20, 28-29 and rejected under 35 U.S.C. 103(a) as being unpatentable over Shvets et al (Theoretical and Experimental Chemistry, Vol 37, No. 2, 2001, 112-115) and/or Schacht et al (Science, Vol 273, 8/9/1996, 768-771, and Bellantone et al (US 6,482,444, filed 6/14/2000).

Regarding claims 1-4, 9-10, Shvets teaches characteristics of template formation in silica in acidic medium. Shvets teaches that the starting materials used were tetraethyl orthosilicate (TEOS) or tetrabutyl orthosilicate (TBOS), cetyltrimethylammonium bromide (CTMABr) or cetyltrimethylammonium chloride (CTMACl) and HCL to adjust the pH of the reaction medium. The composition was prepared as follows: CTMABr was dissolved in HCL and then the solution was transferred to a weighing bottle, TEOS or TBOS was added dropwise, the weighing bottle was closed and kept until the reaction was complete. Fibers first appeared after 5-12 days (depending on the room temperature). The reaction temperature affects particularly the rate of hydrolysis of the orthosilicate and correspondingly the rate of growth of the fibers. Thus on increasing the temperature in the range of 10-24°C the induction time was reduced from 12 to 5 days and completion process from 30 to 10 days. At lower temperatures there was growth of fibers of greater diameter, greater length, and more order. It seems applicant is simply optimizing a well known process for forming silica fibers.

Although Shvets doesn't specifically teach the limitations of claims 1-4 and 9-10, since the process done by Shvets for the formation of fibers seems to be almost identical to the method of forming the fibers of the instant invention and all the same ingredients are utilized, as demonstrated by Example 1, it's expected that the properties of the fibrous preform of the instant application are also properties of the fibers created by Shvets.

Schacht teaches oil-water interface templating of mesoporous macroscale structures. Silica fibers are created dissolving C16H33N(CH3)3Br (synonymous to CTMBr) in HCl. To this solution TEOS is added slowly over 30 min. During this time an emulsion forms. Under slow forming, predominantly fiber-type morphologies are formed (768, col 3, par. 3; 769, col 1, par 1). The particles are in fact hollow after the organic phase has been removed (Pg 769, par 3). The hollow spheres could be used for controlled drug delivery systems. The membranes might be developed further for separation processes, where nanometer-scale pores are needed (Pg 771, Par 1).

Although Schacht's doesn't specifically teach the limitations of claims 1-4 and 9-10, since the process done by Shvets for the formation of fibers is seems to be almost identical to the method of forming the fibers of the instant invention and all the same ingredients are utilized, as demonstrated by Example 1, it's expected that the properties of the fibrous preform of the instant application are also properties of the fibers created by Schacht's.

Shvets and Schacht's fail to teach the fibrous composite to comprise biodegradable polymers, a bioactive agent or to be used to deliver a bioactive agent to an animal using a controlled release delivery system.

Regarding claims 1 and 5, Bellantone discloses a bioactive, biodegradable composite material comprising a fibrous composite of oxides and biodegradable polymers, such as polylactic/polyglycolic acid, wherein fibers of the porous composite comprise gel-like oxide materials with nanometer-sized pores (Col 6, lines 36 and 60-61; Col 7, lines 23-25; and Col 8, lines 23-25).

Art Unit: 1619

Regarding claims 2-3, the oxides comprise SiO₂ and ClO and are bioactive and capable of inducing bone-like apatite growth (Col 2, lines 51-65; Col 3, lines 46-50).

Regarding claims 6-7, 28, and 31, Bellantone discloses the inclusion of a drug or a therapeutic composition to be delivered from the fibrous porous composite at a controlled rate (Col 7, lines 49-57; Col 15, lines 64-66). The drug or therapeutic composition can comprise bone morphogenic proteins (Col 7, lines 62-63).

It would have been prima facie obvious to one of skill in the art at the time the invention was made to combine the teachings of Schacht, Bellantone and Shvet to arrive at the instant invention. One of skill in the art would have been motivated to substitute the silica fibers taught in Bellantone for the silica fibers taught by Shvet or Schacht, since both Shvet/Schacht produce nearly identical fibers as their methods of making and ingredients used are practically identical. One would have been motivated to do so because, Schacht teaches that the silica fibers produced are hollow fibers which can be used in controlled drug delivery systems. Since the process taught by Shvet is similar to that of the instant invention and that of Schacht, it's expected that the silica fibers of Shvet are also hollow fibers useful for controlled drug delivery systems. One of skill in the art would expect reasonable success because Shvet/Schahcts and Bellantone teach fibrous composites of oxides useful for controlled release delivery systems.

Regarding claims 11, 20 and 29 it would have been obvious to one of skill in the art that in order to deliver the bioactive agent incorporated on the fibrous composite of claim 1, the composite must be administered to the patient in need.

With regards to the limitations of effecting release of the bioactive agent in an animal upon degradation of the fibrous porous composite, this is an expected property of the fibrous composite. Since the Shvet/Schacht's and Bellantone teach a fibrous porous composite similar to the fibrous composite of the instant invention, both comprising the same fibrous preform, bioactive agent and physical properties, it's expected that the composite taught by Shvet/Schachts/Bellatone would also have the same degradation properties as the composite taught by the instant invention.

6. Claims 27 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Shvets et al (Theoretical and Experimental Chemistry, Vol 37, No. 2, 2001, 112-115) and/or Schacht et al (Science, Vol 273, 8/9/1996, 768-771, and Bellantone et al (US 6,482,444, filed 6/14/2000) as applied to claim 1-7, 9-11, 20, 28-29 above, and further in view of Aloha et al (WO 97/45367).

Shvets/Schachts/Bellantone teach all the limitations of claims 20 and 11, upon which claims 27 and 30 depend on, but fail to teach the limitations further recited by claims 27 and 30.

With respect to claims 1 and 5, Ahola et al. discloses a bioactive, biodegradable composite material comprising a fibrous composite of oxides and biodegradable polymers (polylactic acid), wherein fibers of the fibrous composite

Art Unit: 1619

comprise gel-like oxide materials with nanometer-sized pores (pg. 5, lines 19-27; pg. 10, lines 1-10, 18-25; pg. 13, line 27 – pg. 14, line 1; pg. 14, lines 16-18).

With respect to claims 6 and 11, Ahola et al. discloses the inclusion of a drug or therapeutic composition to be delivered at a controlled rate from the fibrous composite (col. 4, lines 29-32; col. 10, lines 12-14, 26-30).

With respect to claim 7, Ahola et al. discloses the therapeutic composition comprises bone morphogenic protein (pg. 6, lines 10-11, 34-36).

With respect to claims 20 and 21, Ahola et al. discloses the drug or therapeutic composition is administered to an animal (human or animal body) at a site needed (pg. 4, line 10-12, 32 - pg. 5, line 5).

It would have been prima facie obvious to one of skill in the art at the time the invention was made to combine the teaching of Shvet/Schachts/Bellantone and Aloha to arrive at the instant invention. One of skill in the art would have been motivated to administer the fibrous composite taught by Shvet/Schachts/Bellantone to a human, as suggested by Aloha. One in the art would expect reasonable success because both Aloha and Shvet/Schachts/Bellantone teach fibrous composites of oxides and biodegradable polymers, comprising bioactive agents (bone morphogenic proteins) to be released at a controlled rate.

Conclusion

7. No claims are allowable.

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer A. Berríos whose telephone number is (571)270-7679. The examiner can normally be reached on Monday-Thursday: 7:00am-4:00pm (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1619

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JB

/MP WOODWARD/
Supervisory Patent Examiner, Art Unit 1615